Organigram to Acquire Aurora Cannabis in C$561 Million Deal, Topping Curaleaf’s Hostile Takeover Offer
Organigram will acquire Aurora Cannabis for C$561M (US$398M) at C$7.80 per share, a 93% premium over Aurora's unaffected price and 21% premium over Curaleaf's offer. The deal, approved by both boards, is expected to close in January 2027. Aurora shareholders can choose cash, stock, or a mix. British American Tobacco is financing part of the acquisition.
How this was made
The 30-second read
Why it matters
For ACB, the signed premium offer and hostile-bid expiration create a clear valuation anchor, while approval and regulatory/court risk remain the key swing factors. For OGI, the deal’s financing commitments and expected operating benefits are the primary drivers, but execution and integration risk can still affect the spread.
Market read
A signed, premium acquisition agreement with explicit per-share consideration and active hostile-bid context is a direct catalyst for takeover valuation and approval-probability trading.
What to watch
Financing structure details (private placement terms and credit facility conditions) and the December shareholder vote thresholds could drive volatility even after the agreement is announced.
Background
The article describes Organigram’s agreed acquisition of Aurora, framed as topping Curaleaf’s hostile takeover attempt, with board approvals and a defined consideration mix.
Ticker impact
Organigram agreed to acquire Aurora in a C$561 million deal, offering Aurora shareholders C$7.80 per share and financing via a private placement.
Likely upward bias as markets price in deal certainty and the premium versus Curaleaf’s bid.
The article discloses a signed acquisition agreement with board approvals, defined consideration, and committed financing, which are typically immediate positive catalysts for the acquirer.
Aurora is the target in Organigram’s acquisition, with shareholders offered C$7.80 per share and voting/regulatory approvals expected by January 2027.
Likely upward pressure toward the deal consideration as the market weighs approval odds and deal mechanics versus the hostile bidder’s expiration.
The article provides the all-outstanding-shares offer price, premium metrics versus prior unaffected price, and the hostile bid expiration date, all of which directly affect ACB’s takeover valuation.
Market effects
Signed consolidation in Canadian cannabis can shift sentiment toward M&A optionality and balance-sheet financing among cannabis operators.
Potentially supportive for Canadian cannabis equities as the combined entity targets multiple international medical markets.
International footprint expansion (Germany, Australia, New Zealand) may influence cross-border investor appetite for regulated medical cannabis platforms.
Counterpoint
Deal certainty may be overstated; regulatory or court outcomes and hostile-bid dynamics can still force renegotiation or delay, limiting near-term follow-through.
Key entities
- acquirerOrganigram Global
Agreed to acquire Aurora in a C$561 million transaction, offering C$7.80 per Aurora share and financing via private placement and credit facilities.
- targetAurora Cannabis
Target of the acquisition, offering shareholders cash and/or Organigram shares, subject to shareholder, regulatory, and court approvals.
- hostile bidderCuraleaf Holdings
Competing hostile takeover offer referenced as being topped by Organigram’s agreement, with an expiration date of December 4 unless extended.
- financing participantBritish American Tobacco
Agreed to invest about C$187.5 million via a private placement of Organigram securities to fund the cash portion and expenses.
- financing participantATB Financial
Committed credit facilities up to C$210 million to support the acquisition.
